Rating Downgrade Details

CARE Ratings has downgraded Hester Biosciences Limited's credit ratings for its bank facilities. The long-term rating was revised from 'CARE BBB+; Stable' to 'CARE BBB; Stable', while the short-term rating moved from 'CARE A2' to 'CARE A3+'. These changes affect rated amounts totaling ₹66.25 crore for long-term facilities and ₹65.00 crore for combined long-term/short-term facilities, plus ₹0.22 crore for short-term facilities.

Impact of the Downgrade

A credit rating downgrade typically signals increased risk for lenders. This can potentially lead to higher interest rates on new or refinanced debt and may result in stricter loan covenants. It can also affect investor sentiment, prompting a closer look at the company's financial health and future prospects.

Company Background and Financials

The downgrade follows CARE Ratings' previous affirmation of 'BBB+; Stable' and 'A2' ratings in December 2024. Hester Biosciences is a key player in India's animal healthcare sector, recognized as the second-largest poultry vaccine manufacturer domestically. The company has been developing a locally produced Avian Influenza (H9N2) vaccine, having licensed the technology in late 2022 and secured a manufacturing license in January 2026.

Financially, Hester has shown mixed performance. While its capital structure remains solid with improved overall gearing, profitability metrics like ROCE and ROE are moderate. The company recently experienced its first revenue contraction in three years during fiscal year 2025, alongside a history of weak profit growth over the past three years.

Potential Effects of Rating Change

Hester Biosciences may face increased interest rates on new or refinanced debt. Banks might increase their scrutiny of the company's financial health and compliance. While not immediately critical, prolonged downgrades could eventually limit access to certain types of financing, and investors might become more cautious about the company's creditworthiness and financial execution.

Key Risks for Investors

CARE Ratings can revise or withdraw ratings based on future information, potentially leading to further downgrades or outlook changes. If Hester Biosciences fails to provide necessary information for monitoring, its ratings could be flagged as "ISSUER NOT COOPERATING." Additionally, the introduction and subsequent triggering of rating-related clauses in loan facilities could increase volatility and trigger further sharp downgrades.

Competitive Landscape

Hester Biosciences operates in the animal health sector alongside companies such as Indian Immunologicals Limited (IIL), known for vaccine production, and Venkateshwara Hatcheries Group (Venky's), strong in poultry health. Other key players include the animal health division of Intas Pharmaceuticals and global entities like Virbac Animal Health. Hester holds significant domestic market share in PPR and Goat Pox vaccines and is a major poultry vaccine manufacturer.

Key Rating Data

• Previous Long-Term Rating: CARE BBB+; Stable (December 2024).
• Previous Short-Term Rating: CARE A2 (December 2024).
• Rated Amount (Long-Term/Short-Term Bank Facilities): ₹65.00 crore.
• Rated Amount (Long-Term Bank Facilities): ₹66.25 crore.

Looking Ahead: What to Monitor

Investors will be watching Hester Biosciences' future quarterly results for signs of improved operating and net profit margins and ROCE, which would validate the company's view of a 'transitional' phase. Monitoring the company's debt levels and interest coverage ratios is also important. Tracking the market uptake and revenue contribution from the recently licensed Avian Influenza H9N2 vaccine will be crucial. Finally, any subsequent rating reviews or actions from CARE Ratings should be observed.